<DOC>
	<DOCNO>NCT00006111</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining surgery chemotherapy radiation therapy may effective way treat cancer urinary tract . PURPOSE : Phase II trial study effectiveness combine surgery , chemotherapy radiation therapy treat patient stage II , stage III , stage IV cancer urinary tract .</brief_summary>
	<brief_title>Surgery Plus Combination Chemotherapy Radiation Therapy Treating Patients With Cancer Urinary Tract</brief_title>
	<detailed_description>OBJECTIVES : I. Assess quality life patient invasive stage II , III , IV carcinoma urothelium treat conservative surgery plus cisplatin , fluorouracil , radiotherapy . II . Determine efficacy regimen , term local control , patient . III . Determine survival patient treat regimen . IV . Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients stratify accord tumor type ( T2-4a , N0 , M0 ; potentially resectable ; contraindication surgery v T2-4b , N0 N1 pN1 , M0 ; refuse surgery medical contraindication surgery ) . ( Accrual stratum I complete 10/23/2001 . ) Stratum I ( resectable disease ) : Regimen A : Patients undergo radiotherapy 5 day week 5 week . Patients also receive fluorouracil IV continuously cisplatin IV continuously day 1-4 week 1 4 . If complete response achieve week 5 , patient proceed regimen B . If partial response progression observe , patient undergo cystectomy . If cystectomy refuse , patient proceed regimen B . Regimen B : Patients undergo radiotherapy 5 day week 2 week . Patients also receive fluorouracil cisplatin regimen A week 2 5 . ( Accrual stratum I complete 10/23/2001 . ) Stratum II ( unresectable disease ) : Patients undergo radiotherapy 5 day week 7 week . Patients also receive fluorouracil cisplatin regimen A week 1 , 4 , 7 . Quality life assess baseline , 6 month , 1 year . Patients follow 6-8 week , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 75 patient ( 35 stratum I 40 stratum II ) accrue study . ( Accrual stratum I complete 10/23/2001 . )</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II , III , IV carcinoma urothelium infiltrate muscle Primary OR After development superficial tumor T2T4b without lymph node involvement detectable metastases No epidermoid cancer adenocarcinoma No extrapelvic lymph node involvement PATIENT CHARACTERISTICS : Age : 18 70 Performance status : WHO 02 Life expectancy : More 6 month Hematopoietic : WBC great 4,000/mm3 Platelet count great 100,000/mm3 Neutrophil count great 1,500/mm3 Hemoglobin great 10 g/dL Hepatic : Not specify Renal : Creatinine le 1.5 mg/dL Other : Not pregnant Fertile patient must use effective contraception 2 month study No prior malignancy except nonmelanomatous skin cancer carcinoma situ cervix No prior serious illness gastrointestinal tract ( e.g. , rectal bleeding diverticulosis complication ) No contraindication fluorouracil , cisplatin , radiotherapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy except intravesicular instillation Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
</DOC>